Amarin’s Vascepa nabs ADA backing to cut heart risks, even ahead of FDA review
admin 28th March 2019 Uncategorised 0The cardiovascular outcomes results Amarin rolled out for its fish oil-derived Vascepa may not have impressed everyone, but one leading U.S. health organization is ready to throw its weight behind the drug, even before the FDA weighs in on its CV label expansion.
More: Amarin’s Vascepa nabs ADA backing to cut heart risks, even ahead of FDA review
Source: fierce